Is it Time to Transform our Treatment of Type 2 Diabetes? - European Medical Journal


Is it Time to Transform our Treatment of Type 2 Diabetes?

Download as | PDF
Michael Nauck,1 Dídac Mauricio,2 Anthony Barnett3
Tina Vilsbøll,4 Samy Hadjadj,5 Peter Rossing,6 Edoardo Mannucci,7 Harald Darius,8 Chantal Mathieu9

Speakers participating in this symposium received honorarium from Bristol-Myers Squibb.


Writing assistance provided by Dr Jonathan Viney.


The publication of this article was funded by Bristol-Myers Squibb. The views and opinions expressed are those of the authors and not necessarily of Bristol-Myers Squibb.

EMJ Diabet. ;1[1]:22-29.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

This meeting comprised two sessions: the morning session centred around glucagon-like peptide-1 receptor (GLP-1R) agonists and SGLT-2 inhibitors, a new class of glucose-lowering compounds, while the afternoon session focused on new results of cardiovascular safety studies with diabetes medications, with special attention to the SAVOR-TIMI trial of saxagliptin.

Please view the full content in the pdf above.